YOU’RE INVITED:

CARBOPLATIN & OXALIPLATIN-BASED REGIMENS: SHOULD NK1RA* BE USED?

AGENDA (1 HOUR):
8:00 – 8:35pm  Presentation on Carboplatin & Oxaliplatin-Based Regimens: Should NK1RA* be used?
8:35 – 8:45pm  Case sharing
8:45 – 9:00pm  Q&A

SPEAKER: PROFESSOR KARIN JORDAN
Department of Haematology and Oncology
University Hospital Heidelberg, Germany

Professor Jordan has served as a board member of MASCC/ESMO Antiemetic Guideline Consensus Panel since 2009, and is in the ASCO antiemetic guideline panel. She holds the co-chair of Supportive Care study group within the German Society of Medical Oncology (AIO) and is the associate chair of the German Association of Supportive Care in Oncology (AGSMO).

Professor Jordan is a member of the ESMO Council and Chair of the Educational Committee and a member of the Leadership Generation Task Force. She is a Subject Editor for the Supportive Care section of the ESMO Clinical Practice Guidelines and also a member of the Guidelines Steering Committee. Since 2014, she serves as an Associate Editor of Annals of Oncology and since 2018 as a member of the Editorial Board of ESMO Open.

Professor Jordan has authored and co-authored more than 200 publications and her major area of interest is supportive care with a special focus on antiemetic treatment of chemotherapy-induced nausea and vomiting and side effects of new drugs.

OVERVIEW:

The NCCN has recently reclassified Carboplatin emetogenicity according to the AUC (target area under the concentration versus time curve) with a carboplatin AUC ≥4 classified as highly emetogenic.¹

Oxaliplatin, on the other hand, is classified as moderately emetogenic chemotherapy (MEC) but may be considered highly emetogenic in certain patients.¹

In this webinar session, we will be discussing whether NK1RA should be considered in patients who are receiving Carboplatin or Oxaliplatin-based regimens.


* NK1RA: Neurokinin-1 Receptor Antagonist; NCCN: National Comprehensive Cancer Network; ASCO: American Society of Clinical Oncology; MASCC: Multinational Association for Supportive Care in Cancer

For enquiries, please contact Mundipharma for further details:
Mundipharma (Hong Kong) Limited
Units 801B-802A, 8/F., Tower B, Manulife Financial Centre, 223-231 Wai Yip Street, Kwun Tong, Kowloon
Tel: 852 3929 4666  Fax: 852 3929 4668

CME/CPD Accreditation:
• Hong Kong College of Radiologists, 1 (Cat. A) CME/CPD point
• At Registration link, please click “I agree” box to consent to sharing your contact details with your local Mundipharma for CME/CPD arrangement